Hans Ehrencrona

List of Publications by Year
in descending order

88	7,525	71061 41	54882 84
papers	citations	h-index	g-index

90	90	90	11481
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	PDGF-A Signaling Is a Critical Event in Lung Alveolar Myofibroblast Development and Alveogenesis. Cell, 1996, 85, 863-873.	13.5	787
2	PDGF-C is a new protease-activated ligand for the PDGF Î±-receptor. Nature Cell Biology, 2000, 2, 302-309.	4.6	548
3	Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncology, The, 2018, 19, 747-757.	5.1	444
4	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	3.8	390
5	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€“negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	9.4	309
6	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
7	Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia, 2015, 29, 999-1003.	3.3	280
8	Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	0.8	270
9	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	3.0	242
10	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
11	Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nature Medicine, 2019, 25, 1526-1533.	15.2	218
12	Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia, 2017, 31, 1108-1116.	3.3	201
13	A specific requirement for PDGF-C in palate formation and PDGFR-Î± signaling. Nature Genetics, 2004, 36, 1111-1116.	9.4	199
14	Combination of pegylated IFN-Î±2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood, 2011, 118, 3228-3235.	0.6	174
15	Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood, 2009, 113, 4497-4504.	0.6	173
16	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.4	169
17	Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood, 2010, 116, e111-e117.	0.6	141
18	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125

#	Article	IF	Citations
19	PDGFB Regulates the Development of the Labyrinthine Layer of the Mouse Fetal Placenta. Developmental Biology, 1999, 212, 124-136.	0.9	108
20	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. Journal of the National Cancer Institute, 2020, 112, 1242-1250.	3.0	106
21	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Human Mutation, 2019, 40, 1557-1578.	1.1	102
22	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2009, 18, 4442-4456.	1.4	99
23	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	5.8	93
24	Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer. PLoS Biology, 2011, 9, e1001199.	2.6	91
25	FANCMc.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Human Molecular Genetics, 2015, 24, 5345-5355.	1.4	91
26	Impact of TP53 mutation and 17p deletion in mantle cell lymphoma. Leukemia, 2011, 25, 1904-1908.	3.3	88
27	Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood, 2011, 118, 5905-5913.	0.6	83
28	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
29	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2011, 13, R110.	2.2	71
30	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321.	1.4	68
31	Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phaseâ€‰2 study (<scp>N</scp>ord<scp>CML</scp>006). European Journal of Haematology, 2015, 94, 243-250.	1.1	61
32	Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia, 2013, 27, 1520-1526.	3.3	60
33	Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility. Genetics in Medicine, 2018, 20, 452-457.	1.1	59
34	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	2.2	57
35	Bilateral Prophylactic Mastectomy in Swedish Women at High Risk of Breast Cancer. Annals of Surgery, 2011, 253, 1147-1154.	2.1	54
36	Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. Nature Communications, 2020, 11, 3747.	5.8	53

#	Article	IF	Citations
37	The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. Journal of Medical Genetics, 2018, 55, 15-20.	1.5	50
38	RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib. Leukemia, 2014, 28, 977-979.	3.3	49
39	Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657.	1.1	47
40	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	1.5	47
41	Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial. Blood, 2016, 128, 787-787.	0.6	43
42	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.4	39
43	Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study. Blood, 2014, 124, 151-151.	0.6	38
44	Association of the VariantsCASP8D302H andCASP10V410I with Breast and Ovarian Cancer Risk inBRCA1andBRCA2Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2859-2868.	1.1	37
45	Distinct transcriptional control in major immunogenetic subsets of chronic lymphocytic leukemia exhibiting subset-biased global DNA methylation profiles. Epigenetics, 2012, 7, 1435-1442.	1.3	37
46	Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers. Human Mutation, 2012, 33, 690-702.	1.1	34
47	Clinical and cytogenetic features of a populationâ€based consecutive series of 285 pediatric Tâ€cell acute lymphoblastic leukemias: Rare Tâ€cell receptor gene rearrangements are associated with poor outcome. Genes Chromosomes and Cancer, 2009, 48, 795-805.	1.5	33
48	Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells. Blood, 2014, 124, 812-812.	0.6	33
49	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics, 2011, 20, 4732-4747.	1.4	32
50	Highâ€resolution genomic screening in mantle cell lymphomaâ€”specific changes correlate with genomic complexity, the proliferation signature and survival. Genes Chromosomes and Cancer, 2011, 50, 113-121.	1.5	29
51	Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. British Journal of Cancer, 2012, 106, 2016-2024.	2.9	27
52	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26
53	The frequency and prognostic impact of dic(9;20)(p13.2;q11.2) in childhood B-cell precursor acute lymphoblastic leukemia: results from the NOPHO ALL-2000 trial. Leukemia, 2011, 25, 622-628.	3.3	25
54	Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Research, 2011, 13, R40.	2.2	23

#	Article	IF	Citations
55	Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers. Breast Cancer Research, 2012, 14, R63.	2.2	22
56	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	1.1	22
57	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Human Genetics, 2011, 130, 685-699.	1.8	18
58	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
59	Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1032-1038.	1.1	16
60	Stability of Conversion Factors for BCR-ABL Monitoring -â€“ Implications for the Frequency of Validation Rounds. Blood, 2010, 116, 893-893.	0.6	16
61	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). British Journal of Cancer, 2009, 101, 2048-2054.	2.9	15
62	Mantle cell lymphoma displays a homogenous methylation profile: A comparative analysis with chronic lymphocytic leukemia. American Journal of Hematology, 2012, 87, 361-367.	2.0	13
63	Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS ONE, 2012, 7, e35706.	1.1	11
64	Public support for healthcare-mediated disclosure of hereditary cancer risk information: Results from a population-based survey in Sweden. Hereditary Cancer in Clinical Practice, 2020, 18, 18.	0.6	11
65	The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases. Cancers, 2020, 12, 292.	1.7	11
66	FINAL Analysis of a PAN European STOP Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI Study. Blood, 2021, 138, 633-633.	0.6	10
67	Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries. Familial Cancer, 2018, 17, 31-41.	0.9	9
68	No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial. Blood, 2016, 128, 789-789.	0.6	9
69	Analysis of Mice Lacking the Heparin-Binding Splice Isoform of Platelet-Derived Growth Factor A. Molecular and Cellular Biology, 2013, 33, 4030-4040.	1.1	8
70	How to Handle Genetic Information: A Comparison of Attitudes among Patients and the General Population. Public Health Genomics, 2010, 13, 396-405.	0.6	7
71	Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. British Journal of Cancer, 2011, 104, 1356-1361.	2.9	7
72	Response: high ERG gene expression is an unfavorable prognostic marker in pediatric acute myeloid leukemia. Blood, 2012, 119, 1087-1088.	0.6	7

#	Article	IF	Citations
73	Cliniciansâ€™ use of breast cancer risk assessment tools according to their perceived importance of breast cancer risk factors: an international survey. Journal of Community Genetics, 2019, 10, 61-71.	0.5	7
74	Uâ€2973, a novel Bâ€cell line established from a patient with a mature Bâ€cell leukemia displaying concurrent t(14;18) and MYC translocation to a nonâ€IG gene partner. European Journal of Haematology, 2008, 81, 218-225.	1.1	6
75	Extended genetic diagnostics for children with profound sensorineural hearing loss by implementing massive parallel sequencing. Diagnostic outcome, family experience and clinical implementation. International Journal of Pediatric Otorhinolaryngology, 2022, 159, 111218.	0.4	5
76	Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2012, 136, 295-302.	1.1	4
77	Dasatinib Treatment Induces Fast and Deep Responses In Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients In Chronic Phase: Clinical Results From a Randomized Phase 2 Study (NordCML006). Blood, 2013, 122, 4032-4032.	0.6	4
78	A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients. Scientific Reports, 2021, 11, 14763.	1.6	3
79	Mature, Adaptive-like CD56DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission. Blood, 2015, 126, 343-343.	0.6	3
80	Hereditary colorectal cancer diagnostics in southern Sweden: retrospective evaluation and future considerations with emphasis on Lynch syndrome. Journal of Community Genetics, 2019, 10, 259-266.	0.5	2
81	A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy.. Blood, 2009, 114, 3280-3280.	0.6	2
82	Whole-genome-amplified DNA as a source for mutational analysis underestimates the frequency of mutations in pediatric acute myeloid leukemia. Leukemia, 2013, 27, 510-512.	3.3	1
83	Functional implications of the p.Cys680Arg mutation in the MLH1 mismatch repair protein. Molecular Genetics & Genomic Medicine, 2014, 2, 352-355.	0.6	1
84	Variations in the Referral Pattern for Genetic Counseling of Patients with Early-Onset Breast Cancer: A Population-Based Study in Southern Sweden. Public Health Genomics, 2020, 23, 100-109.	0.6	1
85	Genetic testing in women with early-onset breast cancer: a Traceback pilot study. Breast Cancer Research and Treatment, 2021, 190, 307-315.	1.1	1
86	Abstract P6-10-03: Bilateral Prophylactic Mastectomy in Swedish Women at High Risk of Breast Cancer â€” A National Survey. , 2010, , .		1
87	Genome-Wide Array-Based Methylation Profiling Reveals Preferential Methylation of Homeobox Transcription Factor Genes In Mantle Cell Lymphoma and Pro-Apoptotic Genes In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 536-536.	0.6	0
88	Potential of Digital PCR in CML Calibration. Blood, 2014, 124, 1817-1817.	0.6	0